Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms ZW38 |
Target |
Action inhibitors, stimulants |
Mechanism CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors), CD3 stimulants(T cell surface glycoprotein CD3 stimulants) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
B-Cell Lymphoma | Preclinical | - | 02 Dec 2016 | |
CD19 positive B-Cell Lymphoma | Preclinical | Canada | 20 May 2015 |